Drugs / NRM-823
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07182149 | Oct 2025 → May 2027 expected | cervical cancer, endometrial cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma +6 | Normunity AccelCo, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRM-823 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07182149 ↗ |